ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021
Geneva, Switzerland and Boston, MA – May 31, 2021– ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that shareholders approved all Board proposals at its 2021 Annual General Meeting held on May 28, 2021.
The approved items are as follows:
- Shareholders approved the Annual Report, the Statutory Financial Statements and the Consolidated Financial Statements for Fiscal Year 2020
- Shareholders granted discharge to the Members of the Board of Directors and to the Executive Committee for year 2020
- Shareholders approved the proposed appropriation of the Financial Results for year 2020
- Shareholders approved the proposed elections to the Board of Directors and election of the Chairman of the Board of Directors
- Shareholders approved the proposed elections to the Compensation Committee
- Shareholders approved the re-election of PricewaterhouseCoopers SA as ObsEva SA’s Auditors and Independent Registered Public Accounting Firm
- Shareholders approved the re-election of Perréard de Boccard SA as Independent Representative
- Shareholders approved the proposed compensation of the Board of Directors and the Executive Committee
- Shareholders approved the proposed increase of ObsEva SA’s Authorized Share Capital
- Shareholders approved the proposed increase of ObsEva SA’s Conditional Share Capital for Financing Purposes
- Shareholders approved the proposed increase of ObsEva SA’s Conditional Share Capital for Equity Plans
- Shareholders approved the proposed change to ObsEva SA’s Equity Incentive Plan
For a detailed agenda, including items submitted to shareholders’ vote and related proposals of the Board of Directors, please refer to the full invitation, which may be found in the Investors / General Meetings section of the company’s website www.ObsEva.com
To access the general meetings section of the Company’s website, please click here.
To access the AGM 2021 section of the general meetings section directly, please click here.
To access the full invitation to the AGM 2021 directly, please click here.
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office Contact:
Shauna Dillon
+41 22 552 1550
Investor Contact:
Joyce Allaire
+1 (617)-435-6602
#
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Elanders AB: Report from the Annual General Meeting 202419.4.2024 14:18:43 CEST | Press release
The Annual General Meeting, led by Chairman of the Board Dan Frohm, decided to: adopt the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet, discharge the members of the Board and the Chief Executive Officer from liability for the financial year 2023,according to the proposal in the summons, distribute a dividend of SEK 4.15 per share for 2023. The record date for the dividend is proposed to be 23 April 2024 and it is expected that the dividend will be disbursed by Euroclear Sweden AB on 26 April 2024,for the financial year 2024 grant, according to the proposal in the summons, the Board a remuneration of a total of SEK 4,512,600 including reimbursement for committee work, to be divided among the members as presented in the summons,appoint, according to the proposal in the summons, the following members to the Board until the next Annual General Meeting is held in 2025: Carl Bennet (re-election) Ulrika Dellby (re-election) Eva
Elanders AB: Rapport från årsstämman 202419.4.2024 14:18:43 CEST | Pressemelding
Stämman, som leddes av styrelsens ordförande Dan Frohm, beslöt att: fastställa resultat- och balansräkningen samt koncernresultat- och koncernbalansräkningen,bevilja styrelsens ledamöter och verkställande direktören ansvarsfrihet för verksamhetsåret 2023,enligt styrelsens förslag i kallelsen fastställa att utdelning för 2023 lämnas med 4,15 kronor per aktie samt att avstämningsdagen för utdelning är den 23 april 2024, vilket innebär att utdelningen beräknas utsändas genom Euroclear Sweden AB den 26 april 2024,enligt förslaget i kallelsen för verksamhetsåret 2024 bevilja styrelsen arvode inklusive utskottsarbete om totalt 4 512 600 kronor att fördelas inom styrelsen såsom angivits i kallelsen,enligt förslaget i kallelsen till styrelseledamöter för tiden intill dess att årsstämman 2025 hållits utse: Carl Bennet (omval) Ulrika Dellby (omval) Eva Elmstedt (omval) Dan Frohm (omval) Erik Gabrielson (omval) Anna Hallberg (omval) Anne Lenerius (omval) Magnus Nilsson (omval) Johan Trouvé (omval
Ændringer i afdelinger i Værdipapirfonden Sparinvest, herunder suspensioner19.4.2024 13:48:55 CEST | pressemeddelelse
Bestyrelsen i Sparinvest S.A. har på vegne af Værdipapirfonden Sparinvest den 18. december 2023 besluttet at foretage ændringer i afdelingerne Nye obligationsmarkeder og Nye obligationsmarkeder Akk. Ændringerne medfører skift af afdelingsnavn, benchmark og strategi. Efter ændringerne vil afdelingerne udelukkende investere i emerging markets obligationsudstedelser i lokal valuta, og afdelingernes benchmark ændres til: J.P. Morgan ESG GBI-EM (Unhedged in DKK) Custom Index - Nykredit Exclusion List. ISINAfdelingsnavn før ændringAfdelingsnavn efter ændringSpecifikationerDK0060254043Nye obligationsmarkederINDEX Emerging Market Bonds LokalvalutaBørsnoteretDK0060254126Nye obligationsmarkeder Akk. – KL AINDEX Emerging Market Bonds Lokalvaluta Akk. – KL ABørsnoteretDK0062263372Nye obligationsmarkeder Akk. – KL WINDEX Emerging Market Bonds Lokalvaluta Akk. – KL WUnoteret Bestyrelsen i Sparinvest S.A. har på vegne af Værdipapirfonden Sparinvest den 18. december 2023 besluttet at stifte to nye afd
Auction result of Treasury Bonds - RIKB 27 041519.4.2024 13:30:00 CEST | Press release
Series RIKB 27 0415Settlement Date 04/24/2024Total Amount Allocated (MM) 15,129All Bids Awarded At (Price / Yield) 99.293/8.270Total Number of Bids Received 61Total Amount of All Bids Received (MM) 18,679Total Number of Successful Bids 45Number of Bids Allocated in Full 45Lowest Price / Highest Yield Allocated 99.293/8.270Highest Price / Lowest Yield Allocated 99.750/8.090Lowest Price / Highest Yield Allocated in Full 99.293/8.270Weighted Average of Successful Bids (Price/Yield) 99.471/8.200Best Bid (Price / Yield) 99.750/8.090Worst Bid (Price / Yield) 98.876/8.440Weighted Average of All Bids Received (Price / Yield) 99.422/8.220Percentage Partial Allocation (Approximate) 100.00 %Bid to Cover Ratio 1.23
Netcompany - Final transactions in connection with share buyback programme19.4.2024 13:17:11 CEST | Press release
Company announcement No. 17/2024 19 April 2024 Final transactions in connection with share buyback programme On 25 January 2024, Netcompany Group A/S (“Netcompany”) announced that a share buyback programme of up to DKK 150m and a maximum of 1,300,000 shares had been initiated with the purpose of initiating the redistribution of DKK 2bn to shareholders in line with the midterm 2026 targets. The share buyback programme is executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). The share buyback programme was set to end no later than 1 May 2024. Today, Netcompany announces the final transactions carried out under the current share buyback programme. The following transactions have been executed in the period 16 April 2024 to 18 April 2024: Number of shares Average purchase price, DKK Transaction value, DKK 16-04-2024 20,000 258.0